Use este identificador para citar ou linkar para este item:
https://repositorio.ufba.br/handle/ri/4801
Registro completo de metadados
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Martinelli, Reinaldo Pessôa | - |
dc.contributor.author | Pereira, Luiz José | - |
dc.contributor.author | Silva, Oriana Maria Mattos e | - |
dc.contributor.author | Okumura, Alice Setsuko | - |
dc.contributor.author | Rocha, Heonir de Jesus Pereira da | - |
dc.creator | Martinelli, Reinaldo Pessôa | - |
dc.creator | Pereira, Luiz José | - |
dc.creator | Silva, Oriana Maria Mattos e | - |
dc.creator | Okumura, Alice Setsuko | - |
dc.creator | Rocha, Heonir de Jesus Pereira da | - |
dc.date.accessioned | 2011-12-12T12:18:30Z | - |
dc.date.available | 2011-12-12T12:18:30Z | - |
dc.date.issued | 2004 | - |
dc.identifier.issn | 1678-4510 | - |
dc.identifier.uri | http://www.repositorio.ufba.br/ri/handle/ri/4801 | - |
dc.description | p.1365-1372 | pt_BR |
dc.description.abstract | Prednisone is the initial treatment of primary focal segmental glomerulosclerosis. However, when immunosuppressive agents in combination with steroids are used in the treatment of prednisone-dependent and prednisone-resistant patients the remission rate is variable. We report a long-term trial using cyclophosphamide (2.0 to 3.0 mg/kg body weight for 12 weeks) in combination with prednisone (1.0 to 2.0 mg/kg body weight), as compared with prednisone alone for the treatment of prednisone-resistant and frequently relapsing nephrotic syndrome and focal segmental glomerulosclerosis. Fifty-four patients (34 males and 20 females) with a diagnosis of idiopathic nephrotic syndrome and focal segmental glomerulosclerosis, followed-up for an average of 86.1 ± 82.4 months, were evaluated. Complete remission occurred in 20.4% and partial remission in 14.8% of the patients treated with steroids and in 26.7 and 20.0% of the patients treated with cyclophosphamide + prednisone, respectively. Of the 24 prednisoneresistant patients treated with steroids in combination with cyclophosphamide, 33.3% obtained a complete/partial response. At the time of final evaluation, 25% of the patients treated with prednisone and 10.0% of those treated with prednisone in combination with cyclophosphamide had reached end-stage renal disease. Persistent nephrotic syndrome and progressive renal insufficiency were more frequently observed among the patients treated with prednisone alone (50.0 vs 33.3% and 33.3 vs 16.7%, respectively). The treatments were well tolerated and no patient experienced adverse reactions requiring discontinuation of medications. Although open-label and non-randomized, the present trial showed that cyclophosphamide is a reasonable choice for the treatment of primary focal segmental glomerulosclerosis and prednisone-resistant nephrotic syndrome. | pt_BR |
dc.language.iso | en | pt_BR |
dc.subject | Prednisone | pt_BR |
dc.subject | Nephrotic syndrome | pt_BR |
dc.subject | Cyclophosphamide | pt_BR |
dc.subject | Primary glomerular disease | pt_BR |
dc.subject | Focal segmental | pt_BR |
dc.subject | glomerulosclerosis | pt_BR |
dc.title | Cyclophosphamide in the treatment of focal segmental glomerulosclerosis | pt_BR |
dc.title.alternative | Brazilian Journal of Medical and Biological Research | pt_BR |
dc.type | Artigo de Periódico | pt_BR |
dc.identifier.number | 37(9) | pt_BR |
Aparece nas coleções: | Artigo Publicado em Periódico (Faculdade de Medicina) |
Arquivos associados a este item:
Não existem arquivos associados a este item.
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.